Invitrogen Corp.
Invitrogen Corp. of Carlsbad, Calif.,
has entered into an agreement with the National Institutes of Health Chemical Genomics
Center in Bethesda, Md., to identify small molecules that modulate key signaling
pathways associated with disease pathophysiology. The center will use the company’s
CellSensor cell lines and GeneBLAzer β-lactamase reporter gene technology
to identify compounds that modulate disease signaling pathways. All of the data
will be deposited in PubChem, an NIH database that links chemical structures to
biological activities uncovered through screening campaigns. The research community
will have access to the database.
LATEST NEWS
- Method Measures Trapped Qubits While Keeping Others Safe, Close
Sep 26, 2024
- Industrial Laser-Driven Neutron Source Developed for Nondestructive Assessment of Nuclear Waste
Sep 26, 2024
- Glass-Based PICs Developer Expands Following NATO-Supported Funding
Sep 25, 2024
- InZiv Appoints Vice President of R&D: People in the News: 9/25/24
Sep 25, 2024
- Ansys, TSMC, Collaborate with Microsoft on High-Speed Optical Data Transfer
Sep 25, 2024
- Collaboration, Tech Advancement Take Center Stage at Neuroscience 2024
Sep 24, 2024
- HyperLight Lands $37M to Advance Lithium Niobate Tech
Sep 24, 2024
- Integrated Photonics Companies Join Forces, Target Hybrid Solutions Supply Chain
Sep 24, 2024